Compare iShares MSCI India ETF (INDA) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs DENTSPLY SIRONA Inc — how do they compare? iShares MSCI India ETF trades at $46.03 (market cap $5.73B), while DENTSPLY SIRONA Inc trades at $8.83 (market cap $1.73B). The key difference: iShares MSCI India ETF is far larger — about 3.3× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while iShares MSCI India ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI India ETF for 58 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| INDA | XRAY | |
|---|---|---|
Market Cap | $5.73B | $1.73B |
Volume | 6,797,522 | 6,198,582 |
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $14.68 |
52-Week Low | $45.42 | $8.52 |
Typical Hold Time | 58 Days | 72 Days |
Enterprise Value | — | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $46.03, down 0.2% on the day, with a bearish technical signal driven by moving averages and oscillators. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. Recent news highlights India's economic growth amid sector-specific challenges, including energy security concerns and pharmaceutical export hurdles, which may influence the ETF's underlying holdings.
The outlook remains cautious due to technical weakness and macroeconomic headwinds in India. Opportunities exist if oversold conditions reverse, but risks include regulatory tensions and sector volatility. Investors should await updated financials for a clearer fundamental picture.
DENTSPLY SIRONA (XRAY) trades at $8.83, down 3.4% with bearish technical signals. The stock faces fundamental challenges with negative net income margins (-14.99%) and declining revenue trends ($3.68B in 2025). Recent Q2 2026 earnings beat expectations but sales fell 4.1% amid ongoing turnaround efforts. The company maintains strong institutional interest despite hitting 52-week lows in September 2026.
XRAY presents a high-risk opportunity with Wall Street maintaining a cautious stance (37.5% buy rating). The consensus price target of $13.40 offers 52% upside potential, but investors face execution risks in the dental equipment turnaround, margin pressures, and competitive challenges. Near-term catalysts include management's presentation at the Baird Healthcare Conference in September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
